+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Melanoma Therapeutics: Global Markets

  • PDF Icon

    Report

  • 131 Pages
  • November 2023
  • Region: Global
  • BCC Research
  • ID: 5910557

The global market for melanoma treatment was estimated to reach $6.8 billion in 2022 and is expected to reach $12.1 billion through 2028, growing at a CAGR of 10.2% during the forecast period. The melanoma treatment market is segment based on type of treatment, type of therapeutics, treatment by stage and by region. Major players in the market include Merck & Co., Bristol Myers Squibb and Novartis. Apart from the major players there are also small biotech companies such as Erasca, HUYABIO International and IO Biotech that have promising drug candidates in the pipeline, which should push market growth during the forecast period.

The North American region accounted for the highest share of the global market, followed by Europe. In the North American and European regions, key growth factors include increasing prevalence of melanoma, high healthcare expenditures, increasing number of drug approvals, strong pipelines, increasing public awareness and government support. Based on type of treatment, therapeutics accounted for the highest market share in 2022. Based on stage, localized stage accounted for the highest market share in 2022. In the therapeutics segment, immunotherapies accounted for the highest market share in 2022.

The majority of melanoma patients are diagnosed in the localized stage of the disease, for which surgery is the mainstay of treatment. Since 2011, agents such as immunotherapies and targeted therapies have been approved to treat advanced melanoma, increasing patient survival rates. Five-year overall survival (OS) rates for metastatic melanoma have increased substantially, from less than 10% before 2011, to 40% to 50% post-approval of novel therapies. Before novel therapies were introduced, patients received standard chemotherapy, for which the survival rates are than 5% to 6%. Thus, the development of novel treatments, in particular the immunomodulating monoclonal antibodies or the immune-checkpoint inhibitors (anti–CTLA-4, anti-PD-1/PD-L1) and small molecule-targeted therapies (BRAF and MEK inhibitors), has revolutionized the prognosis for patients with advanced melanoma. These targeted and immunotherapies have been approved for use either as monotherapy or as combination therapies with better outcomes.

Despite the efficacy of cancer immunotherapy targeting CTLA4 and PD1/PDL1, a considerable portion of patients (nearly 40%), including those with melanoma, did not respond to immunotherapy. As a result, attention has turned towards exploring different inhibitory targets and suppressive mechanisms present within the tumor microenvironment.

The pipeline for melanoma is strong, with first-in-class molecules that have novel targets. The pipeline also focuses on personalized treatment approaches such as cell therapy and vaccines which aim at treating the disease and reduce the recurrence.

The following market factors are increasing, which is boosting market growth: prevalence of melanoma, strategic initiatives, technological advancements, product launches, early detection tools, patient advocacy groups and public awareness. However, factors restricting market growth include the high cost of treatment, stringent regulations and resistance or poor response to therapies.

Report Scope

This study investigates the melanoma treatment market. The report analyzes melanoma treatment based on treatment type, cancer stage and type of therapeutics. The report determines the current market status in each segment, examines its impact on future needs and presents growth forecasts over the next five years. The report provides a detailed analysis of the market’s drivers, challenges, and opportunities. The report also covers market projections through 2028 and analyzes market share for key market players. In its profiles of key companies, the report provides detailed information about their business segments, financials, product portfolios and recent developments. The report also discusses the market impact of the COVID-19 pandemic, emerging technologies, and new developments, ESG development and investment outlook.</p>

The Report Includes

  • 30 data tables and 18 additional tables
  • An overview of the global market for melanoma treatment
  • Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Description of various treatment options such as chemotherapy, surgical resection, immunotherapy, and targeted therapies; and various treatment approaches for the betterment of patient's overall health
  • A look at the advancements in the genetic profiling of melanocytes and identification of novel molecules that involved in melanoma's development
  • Information on new potential therapeutic target discovery; and description of novel immune checkpoint inhibitors, adoptive cell therapy and engineered TCR therapy
  • Coverage of innovation, technological advancements, and the launch of novel products from market players
  • Detailed analysis of the regulatory framework and policies and product pipeline of the industry, and discussion on ESG challenges in the pharmaceutical industry and ESG practices in the melanoma treatment market
  • Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
  • Comprehensive company profiles of the leading players of the industry, including Amgen, Roche, Merck & Co., Pfizer Inc., BMS, and Novartis AG

Table of Contents

Chapter 1: Introduction
  • Study Goals and Objectives
  • Scope of the Report
  • Reasons for Doing the Study
  • Methodology
  • Information Sources
  • Geographic Breakdown
  • Segmentation Breakdown
Chapter 2: Summary and Highlights
  • Market Outlook
  • Market Summary
Chapter 3: Market and Technology Background
  • Introduction
  • Risk Factors, Causes and Prevention
  • Symptoms
  • Pathophysiology and Clinical Subtypes
  • Prognosis
  • Epidemiology
  • Diagnosis
  • Biopsy
  • Laboratory Tests
  • Blood Tests
  • Imaging Tests
  • Treatment
  • Immunotherapy
  • PD-1 and PD-L1 Inhibitors
  • CTLA-4 inhibitors
  • LAG-3 Inhibitors
  • Interleukin-2 (IL-2, Proleukin)
  • Virus Therapy
  • BRAF inhibitors:
  • MEK Inhibitors
Chapter 4: Market Dynamics
  • Market Factors
  • Market Drivers
    • Increasing Prevalence of Melanoma
    • Technological Advancements and Product Launches
    • Strategic Initiatives
    • Developments in Early Detection Tools
    • Patient Advocacy Groups and Awareness
  • Market Restraints
    • High Cost of Treatment
    • Stringent Regulations
    • Resistance to Therapies
  • Market Opportunities
Chapter 5: Market Breakdown by Type
  • Overview
  • Surgery
  • Wide Excision
  • Mohs Surgery
  • Amputation
  • Lymph Node Dissection
  • Therapeutics
  • Therapeutics by Type
  • Radiation Therapy
Chapter 6: Market Breakdown by Disease Stage
  • Overview
  • Localized Disease
  • Regional Disease
  • Distant Disease
Chapter 7: Market Breakdown by Region
  • Overview
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 8: Sustainability: An ESG Perspective
  • Introduction
  • ESG Challenges in the Pharmaceutical Industry
  • ESG Practices in the Market for Melanoma Therapeutics
  • Environmental Initiatives
  • Social Initiatives
  • Governance Initiatives
  • Case Study
  • Research Viewpoint
Chapter 9: Emerging Technologies/ Developments
  • Introduction
  • Novel Immune Checkpoint Inhibitors
  • Adoptive Cell Therapy
  • Engineered TCR Therapy
  • Vaccines
  • Targeted Therapy
Chapter 10: Regulatory Landscape and Pipeline Analysis
  • Regulatory Landscape
  • United States
  • Europe
  • Japan
  • Pipeline Analysis
Chapter 11: Patent Analysis
  • Patent Review by Year
  • Patent Review by Country
  • Patent Review
Chapter 12: Competitive Landscape
  • Mergers and Acquisitions
  • Strategic Initiatives
  • Competitive Analysis
Chapter 13: Company Profiles
  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • Erasca Inc.
  • F. Hoffmann-La Roche AG
  • Huyabio International
  • Iovance Biotherapeutics Inc.
  • IO Biotech
  • Merck & Co. Inc.
  • Moderna Ina.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
List of Tables
Summary Table A: Global Market for Melanoma Therapeutics, Through 2028
Summary Table B: Global Market for Melanoma Therapeutics, by Region, Through 2028 ($ Millions)
Table 1: List of Approved Therapies for Melanoma
Table 2: Global Melanoma Cancer Statistics, by WHO Region, 2020
Table 3: Global Market for Melanoma Therapeutics, by Type, Through 2028
Table 4: Recommended Margins for Surgical Excision
Table 5: Global Market for Surgical Treatment of Melanoma, by Region, Through 2028
Table 6: Global Market for Melanoma Therapeutics, by Region, Through 2028
Table 7: Global Market for Melanoma Therapeutics, by Type, Through 2028
Table 8: Global Market for Melanoma Therapeutics for Immunotherapy, by Region, Through 2028
Table 9: Global Market for Melanoma Targeted Therapies, by Region, Through 2028
Table 10: Global Market for Melanoma Chemotherapy, by Region, Through 2028
Table 11: Global Market for Melanoma Radiation Therapy, by Region, Through 2028
Table 12: Estimated Costs per Person Diagnosed with Melanoma Over a 5-Year Period, by Disease Stage, 2020
Table 13: Global Market for Melanoma Therapeutics, by Disease Stage, Through 2028
Table 14: Global Market for Melanoma Therapeutics for Localized Disease Stage, by Region, Through 2028
Table 15: Global Market for Melanoma Therapeutics for the Regional Disease Stage, by Region, Through 2028
Table 16: Global Market for Melanoma Therapeutics for the Distant Metastasis Stage, by Region, Through 2028
Table 17: Global Market for Melanoma Therapeutics, by Region, Through 2028
Table 18: North American Market for Melanoma Therapeutics, by Country, Through 2028
Table 19: European Market for Melanoma Therapeutics, by Country, Through 2028
Table 20: Estimated Incidence, Mortality and Prevalence of Melanoma in 2020
Table 21: Asia-Pacific Market for Melanoma Therapeutics, by Country, Through 2028
Table 22: Key ESG Issues in the Pharmaceutical Industry
Table 23: Environmental Initiatives by Various Melanoma Therapeutics Companies
Table 24: ESG Rankings for Companies in the Market for Melanoma Therapeutics for 2023
Table 25: Industry-Leading Performance Across Priority ESG Ratings
Table 26: Melanoma Pipeline: Phase II and Phase III Clinical Trials
Table 27: Patents Issued on Melanoma Therapeutics, by Year, January 2020-August 2023
Table 28: Patents Issued for Melanoma Therapeutics, by Country, 2020-August 2023
Table 29: Patents Issued on Melanoma Therapeutics, by Applicant, 2020-August 2023
Table 30: Mergers and Acquisitions, 2020-2023
Table 31: Amgen: Financials, 2021 and 2022
Table 32: Amgen: Marketed Products
Table 33: BMS: Financials, 2021 and 2022
Table 34: BMS: Marketed Products
Table 35: BMS: News, 2019-2023
Table 36: Roche: Financials, 2021 and 2022
Table 37: Roche: Marketed Products
Table 38: Roche: News, 2022
Table 39: Merck & Co.: Financials, 2021 and 2022
Table 40: Merck & Co.: Marketed Products
Table 41: Merck & Co.: News, 2021-2023
Table 42: Novartis AG: Financials, 2021 and 2022
Table 43: Novartis AG: Marketed Products
Table 44: Pfizer Inc.: Financials, 2021 and 2022
Table 45: Pfizer Inc.: Marketed Products
Table 46: Pfizer Inc.: News, 2021-2023

List of Figures
Summary Figure A: Global Market for Melanoma Therapeutics, 2020-2028
Summary Figure B: Global Market for Melanoma Therapeutics, by Region, 2020-2028
Figure 1: Schematic Diagram of Skin Structure
Figure 2: ABCDE Rule for Melanoma
Figure 3: Melanoma Staging
Figure 4: Melanoma by Stages
Figure 5: Estimated Number of New Skin Melanoma Cases Worldwide for Both Sexes, by Age Group, 2020
Figure 6: Melanoma Therapeutics Algorithm
Figure 7: Global Market for Melanoma Therapeutics, by Type, 2020-2028
Figure 8: Global Market Shares of Melanoma Therapeutics, by Type, 2022
Figure 9: Global Market for Surgical Treatment of Melanoma, by Region, 2020-2028
Figure 10: Timeline of FDA Treatment Approvals in Melanoma
Figure 11: Global Market for Melanoma Therapeutics, by Region, 2020-2028
Figure 12: Global Market for Melanoma Therapeutics, by Type, 2020-2028
Figure 13: Global Market Shares of Melanoma Therapeutics, by Type, 2022
Figure 14: Global Market for Melanoma Therapeutics for Immunotherapy, by Region, 2020-2028
Figure 15: Global Market for Melanoma Targeted Therapies, by Region, 2020-2028
Figure 16: Global Market for Melanoma Chemotherapy, by Region, 2020-2028
Figure 17: Global Market for Melanoma Radiation Therapy, by Region, 2020-2028
Figure 18: Global Market for Melanoma Therapeutics, by Disease Stage, 2020-2028
Figure 19: Global Market Shares of Melanoma Therapeutics, by Disease Stage, 2022
Figure 20: Global Market for Melanoma Therapeutics for Localized Disease Stage, by Region, 2020-2028
Figure 21: Global Market for Melanoma Therapeutics for the Regional Disease Stage, by Region, 2020-2028
Figure 22: Global Market for Melanoma Therapeutics for the Distant Metastasis Stage, by Region, 2020-2028
Figure 23: Global Market for Melanoma Therapeutics, by Region, 2020-2028
Figure 24: Global Market Shares of Melanoma Therapeutics, by Region, 2022
Figure 25: North American Market for Melanoma Therapeutics, by Country, 2020-2028
Figure 26: European Market for Melanoma Therapeutics, by Country, 2020-2028
Figure 27: Asia-Pacific Market for Melanoma Therapeutics, by Country, 2020-2028
Figure 28: RoW Market for Melanoma Therapeutics, 2020-2028
Figure 29: ESG in Market for Melanoma Therapeutics
Figure 30: Novartis ESG Analysis
Figure 31: Clinical Trial Analysis
Figure 32: Shares of Patents Issued on Melanoma Therapeutics, by Year, January 2020 to August 2023
Figure 33: Global Market Shares of Melanoma Therapeutics, by Company, 2022
Figure 34: Amgen: Financials, 2021 and 2022
Figure 35: Amgen: Revenue Share, by Country/Region, 2022
Figure 36: BMS: Financials, 2021 and 2022
Figure 37: BMS: Revenue Share, by Business Unit, 2022
Figure 38: BMS: Revenue Share, by Country/Region, 2022
Figure 39: Roche: Annual Revenue, 2021 and 2022
Figure 40: Roche: Revenue Share, by Business Unit, 2022
Figure 41: Roche: Revenue Share, by Region, 2022
Figure 42: Merck & Co.: Financials, 2021 and 2022
Figure 43: Merck & Co.: Revenue Share, by Business Unit, 2022
Figure 44: Merck & Co.: Revenue Share, by Country/Region, 2022
Figure 45: Novartis AG: Financials, 2021 and 2022
Figure 46: Novartis AG: Revenue Share, by Business Unit, 2022
Figure 47: Novartis AG: Revenue Share, by Region, 2022
Figure 48: Pfizer Inc.: Financials, 2021 and 2022
Figure 49: Pfizer Inc.: Revenue Share, by Business Unit, 2022
Figure 50: Pfizer Inc.: Revenue Share, by Region, 2022

Companies Mentioned

  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • Erasca Inc.
  • F. Hoffmann-La Roche AG
  • Huyabio International
  • Iovance Biotherapeutics Inc.
  • IO Biotech
  • Merck & Co. Inc.
  • Moderna Ina.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.

Table Information